Valuation: NetraMark Holdings Inc.

Market Cap 5.2Cr 3.63Cr 3.31Cr 3.06Cr 2.76Cr 339.35Cr 5.41Cr 37Cr 15Cr 183.16Cr 14Cr 13Cr 578.38Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 5.2Cr 3.63Cr 3.31Cr 3.06Cr 2.76Cr 339.35Cr 5.41Cr 37Cr 15Cr 183.16Cr 14Cr 13Cr 578.38Cr EV / Sales 2026 *
130x
EV / Sales 2027 * -
Free-Float
89.17%
Yield 2026 *
-
Yield 2027 * -
10/09 NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models CI
01/09 Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors CI
14/08 NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
09/07 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
09/07 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
29/06 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
29/06 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
15/05 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
08/05 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
04/05 NetraMark Holdings Inc. Announces Executive Changes CI
22/04 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
20/04 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
09/04 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
1 day-6.78%
1 week-5.17%
Current month-6.78%
1 month-14.06%
3 months-15.38%
6 months-38.20%
Current year-50.00%
1 week 0.55
Extreme 0.55
0.62
1 month 0.48
Extreme 0.48
0.64
Current year 0.48
Extreme 0.48
1.28
1 year 0.48
Extreme 0.48
1.28
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
1.97
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Date Insider Type Main position Quantity % Market Cap. Importance
31/10/26 Tax

General Counsel

6,992 0.0075%
23/09/26 Buy

Chairman

10,000 0.0108%
23/09/26 Buy

Chairman

25,000 0.0270%
Change 5-day change 1-year change 3-year change Capi.($)
-6.78%-5.17%-52.17%+37.50% 3.91Cr
+0.40%-2.46%+2.94%+37.43% 3,75900Cr
0.00%0.00% - - 97TCr
+0.07%-9.12%-6.37%+664.62% 38TCr
-0.97%-11.29%-48.35%-1.27% 36TCr
-3.76%-8.07%-5.57%+41.32% 26TCr
+9.90%+1.63%+69.11%+174.58% 25TCr
+7.95%+3.48%+84.58%+357.83% 23TCr
-2.01%-3.42%-25.68%+899.77% 13TCr
-2.49%-11.84%-44.63%-30.78% 9.64TCr
Average +0.23%-3.20%-2.90%+242.33% 64TCr
Weighted average by Cap. +0.62%-3.77%+3.42%+117.67%

Financials

2026 *2027 *
Net sales 4L 3L 3L 2L 2L 2.61Cr 4L 28.49L 11.26L 1.41Cr 10.49L 10.28L 4.46Cr -
Net income - -
Net Debt - -
Projected Income Statement - Annual - NetraMark Holdings Inc.
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
18/26/18 CA$0.5500 -6.78% 33,763
17/26/17 CA$0.5900 0.00% 4,545
16/26/16 CA$0.5900 -1.67% 10,500
13/26/13 CA$0.6000 0.00% 52,225
12/26/12 CA$0.6000 +3.45% 2,000

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - NetraMark Holdings Inc.
  1. Stock Market
  2. Stocks
  3. AIAI Stock